Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,019Revenue $M2,145Net Margin (%)15.8Z-Score6.7
Enterprise Value $M9,183EPS $2.1Operating Margin %19.4F-Score3
P/E(ttm))25.7Cash Flow Per Share $0Pre-tax Margin (%)20.3Higher ROA y-yN
Price/Book5.810-y EBITDA Growth Rate %32.8Quick Ratio1.5Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %46.8Current Ratio2.0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %18.3ROA % (ttm)16.2Higher Current Ratio y-yN
Dividend Yield %0.5Insider Buy (3m)0ROE % (ttm)24.7Less Shares Outstanding y-yN
Payout Ratio %13.0Shares Outstanding M170ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with RDY

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RDYKen Fisher 2014-06-30 Add0.13%$38.67 - $46.08
($42.03)
$ 52.9426%Add 62.43%3,773,114
RDYKen Fisher 2014-03-31 Add0.08%$39.5 - $47.4
($43.29)
$ 52.9422%Add 56.3%2,322,863
RDYKen Fisher 2013-06-30 Add0.04%$32.98 - $38.7
($36.5)
$ 52.9445%Add 48.42%1,283,605
RDYKen Fisher 2013-03-31 Add0.02%$32.03 - $36.57
($34.21)
$ 52.9455%Add 31.46%864,830
RDYKen Fisher 2012-09-30 Buy 0.05%$28.94 - $32.58
($30.12)
$ 52.9476%New holding, 604555 sh.604,555
RDYBrian Rogers 2007-09-30 Sold Out -0.33%$15.25 - $16.85
($16.1)
$ 52.94229%Sold Out0
RDYBrian Rogers 2007-06-30 Buy 0.33%$15.25 - $17.25
($16.3)
$ 52.94225%New holding, 4250000 sh.4,250,000
RDYMohnish Pabrai 2006-09-30 Sold Out -1.11%$13.55 - $16.04
($15.3)
$ 52.94246%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RDY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
RDY Ken Fisher 2014-09-303,994,8682.340.45+5.88%
Premium Most recent portfolio changes are included for Premium Members only!


RDY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about RDY :

Quarterly/Annual Reports about RDY:

    News about RDY:

    Articles On GuruFocus.com
    Should You Buy Actavis? Mar 18 2014 
    Dr. Reddy’s Laboratories: Should Continue to Gain Market Share in Lucrative Markets May 25 2012 
    5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
    Abbott Laboratories and the “India Cure” for the Ailing Pharmaceutical Industry May 26 2010 
    Dr. Reddy’s Q3 FY09 Revenue at Rs. 18,401 million, EBITDA at Rs. 3,453 million, PAT at Rs. 1,924 m Jan 20 2009 

    More From Our Partners
    Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog Jan 22 2015 - ZACKS

    More From Other Websites
    Curis (CRIS) in Focus: Stock Adds 17.5% in Session - Tale of the Tape Jan 23 2015
    Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog Jan 22 2015
    To Your Health: Pharma Stock Picks In China, India For 2015 Jan 22 2015
    Curis aims for anti-cancer drugs that use the immune system and come in a pill Jan 22 2015
    Dr. Reddy's to Release Q3 FY15 Results on January 29, 2015 Jan 22 2015
    Dr. Reddy's to Release Q3 FY15 Results on January 29, 2015 Jan 22 2015
    As India Market Surges: In Defense of Lofty Valuations Jan 21 2015
    Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and... Jan 21 2015
    India Climbs To Another Record -- Getting Expensive? Jan 21 2015
    Two Banks, Four ETFs Surge As India Cuts Lending Rate Jan 15 2015
    Can India Stocks Top Most World Markets This Year? Jan 08 2015
    Pharma Sales Growth In Emerging Markets Could Top 8%, Margins Need To Improve Jan 06 2015
    Rate Cuts, Reform on Tap in Asia for 2015 Dec 27 2014
    Dr. Reddy’s Laboratories Closes the Acquisition of Habitrol® Brand from Novartis Dec 19 2014
    Dr. Reddy’s Laboratories Closes the Acquisition of Habitrol® Brand from Novartis Dec 19 2014
    Dr. Reddy’s Announces the Launch of Valganciclovir Tablets, USP Dec 16 2014
    Dr. Reddy’s Announces the Launch of Valganciclovir Tablets, USP Dec 16 2014
    India Sensex Index Falls, Hindu Muslim Tensions Rise? Dec 05 2014
    Dr. Reddy’s Announces the Launch of Docetaxel Injection USP Nov 24 2014
    Dr. Reddy’s Announces the Launch of Docetaxel Injection USP Nov 24 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK